Serial Number | 97079346 |
Word Mark | CENTER FOR BREAKTHROUGH MEDICINES AT DISCOVERY LABS |
Filing Date | Monday, October 18, 2021 |
Status | 602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE |
Status Date | Saturday, October 1, 2022 |
Registration Number | 0000000 |
Registration Date | NOT AVAILABLE |
Mark Drawing | 3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
Published for Opposition Date | NOT AVAILABLE |
Description of Mark | The mark consists of an artistic rendition of a molecular line drawing cut off by two horizonal lines to the right are the words CENTER FOR BREAKTHROUGH MEDICINE AT DISCOVERY LABS. |
Goods and Services | Manufacturing services for others in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; manufacturing services for others in the fields of mammalian cell banks, plasmids, adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in humans and animals; manufacturing process consulting |
Goods and Services | Research and development services in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; consulting services in the fields of research and development for gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; research and development of new products for others; process development services in the nature of research and development of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; scientific research and technical research services, namely, production of cell lines for others using lentivirus technology; scientific research and technical research services relating to producing, assaying and purifying recombinant or manipulated lentivirus; Scientific and technical consulting services relating to producing, assaying, and purifying adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in humans and animals; advisory services relating to research and development of gene therapy products and biopharmaceuticals; manufacturing support services for others, namely, cGMP (Current Good Manufacturing Practice) quality control testing in support of biopharmaceutical development and manufacturing; quality control for others; quality management services, namely, quality evaluation and analysis, quality assurance, and quality control, in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; material testing; product quality testing; scientific laboratory services; scientific research |
International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
US Class Codes | 100, 101 |
Class Status Code | 6 - Active |
Class Status Date | Thursday, November 4, 2021 |
Primary Code | 042 |
First Use Anywhere Date | NOT AVAILABLE |
First Use In Commerce Date | NOT AVAILABLE |
International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
US Class Codes | 100, 101 |
Class Status Code | 6 - Active |
Class Status Date | Thursday, November 4, 2021 |
Primary Code | 044 |
First Use Anywhere Date | NOT AVAILABLE |
First Use In Commerce Date | NOT AVAILABLE |
Party Name | CENTER FOR BREAKTHROUGH MEDICINES HOLDINGS, LLC |
Party Type | 11 - New Owner Before Publication |
Legal Entity Type | 16 - Limited Liability Company |
Address | KING OF PRUSSIA, PA 19406 |
Party Name | MORNING LIGHT IP, LLC |
Party Type | 10 - Original Applicant |
Legal Entity Type | 16 - Limited Liability Company |
Address | Radnor, PA 19087 |
Event Date | Event Description |
Monday, October 3, 2022 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND |
Saturday, October 1, 2022 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE |
Friday, March 18, 2022 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
Friday, March 18, 2022 | NON-FINAL ACTION E-MAILED |
Friday, March 18, 2022 | NON-FINAL ACTION WRITTEN |
Friday, March 4, 2022 | ASSIGNED TO EXAMINER |
Wednesday, January 26, 2022 | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
Friday, November 5, 2021 | NOTICE OF DESIGN SEARCH CODE E-MAILED |
Thursday, November 4, 2021 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
Thursday, October 21, 2021 | NEW APPLICATION ENTERED IN TRAM |